|
Consolidated Statements of Operations (USD $)
|
3 Months Ended | 6 Months Ended | 45 Months Ended | ||
|---|---|---|---|---|---|
|
Dec. 31, 2013
|
Dec. 31, 2012
|
Dec. 31, 2013
|
Dec. 31, 2012
|
Dec. 31, 2013
|
|
| Operating expenses | |||||
| Consulting fees | $ 80,751 | $ 110,514 | $ 162,025 | $ 228,155 | $ 1,062,529 |
| Compensation and benefits | 411,879 | 193,306 | 770,332 | 393,872 | 5,406,209 |
| Research and development | 0 | 0 | 0 | 0 | 3,494 |
| Insurance | 44,264 | 4,375 | 89,077 | 8,616 | 207,947 |
| Professional fees | 76,968 | 138,471 | 242,617 | 292,879 | 1,045,560 |
| Rent | 25,887 | 18,531 | 38,749 | 34,323 | 170,701 |
| Travel | 1,941 | 11,630 | 7,396 | 55,211 | 246,529 |
| Amortization | 886 | 0 | 1,772 | 0 | 2,067 |
| General and administrative | 7,542 | 23,238 | 39,053 | 29,892 | 172,121 |
| Total operating expenses | 650,118 | 500,065 | 1,351,021 | 1,042,948 | 8,317,157 |
| Loss from operations | (650,118) | (500,065) | (1,351,021) | (1,042,948) | (8,317,157) |
| Other income (expense) | |||||
| Interest income | 3,379 | 71,972 | 6,833 | 88,902 | 144,424 |
| Interest expense | (623,347) | (109,421) | (788,164) | (214,319) | (1,818,328) |
| Derivative expense | (548,556) | 0 | (505,821) | 0 | (663,582) |
| Total other income (expense) | (1,168,524) | (37,449) | (1,287,152) | (125,417) | (2,337,486) |
| Net loss | $ (1,818,642) | $ (537,514) | $ (2,638,173) | $ (1,168,365) | $ (10,654,643) |
| Net loss per common share - basic and diluted | $ (0.05) | $ (0.02) | $ (0.07) | $ (0.03) | $ (0.29) |
| Weighted average number of common shares outstanding - basic and diluted | 40,000,000 | 35,284,000 | 40,000,000 | 35,284,000 | 36,415,569 |
| X | ||||||||||
|
- Definition
Expenses incurred for consulting fees during the period. No definition available.
|
| X | ||||||||||
|
- Definition
Interest income. No definition available.
|
| X | ||||||||||
|
- Definition
Payroll Expenses. No definition available.
|
| X | ||||||||||
|
- Definition
Travel Expenses. No definition available.
|
| X | ||||||||||
|
- Definition
Weighted Average Number Basic and Diluted Shares Outstanding. No definition available.
|
| X | ||||||||||
|
- Definition
The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. No definition available.
|
| X | ||||||||||
|
- Definition
The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The expense in the period incurred with respect to protection provided by insurance entities against risks other than risks associated with production (which are allocated to cost of sales). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount of the cost of borrowed funds accounted for as interest expense. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line. No definition available.
|
| X | ||||||||||
|
- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. No definition available.
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
The net result for the period of deducting operating expenses from operating revenues. No definition available.
|
| X | ||||||||||
|
- Definition
Amount of general expenses not normally included in Other Operating Costs and Expenses. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|